Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $549288.0.

  • Gain Therapeutics' Tax Provisions rose 489352.73% to $549288.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 268145.33%. This contributed to the annual value of $536815.0 for FY2024, which is 57715.55% up from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Tax Provisions is $549288.0, which was up 489352.73% from $141205.0 recorded in Q2 2025.
  • Gain Therapeutics' Tax Provisions' 5-year high stood at $549288.0 during Q3 2025, with a 5-year trough of -$8244.0 in Q4 2021.
  • Its 5-year average for Tax Provisions is $79162.3, with a median of $14502.0 in 2023.
  • Per our database at Business Quant, Gain Therapeutics' Tax Provisions crashed by 50263.16% in 2021 and then surged by 1157948.72% in 2025.
  • Gain Therapeutics' Tax Provisions (Quarter) stood at -$8244.0 in 2021, then soared by 1047.42% to $78105.0 in 2022, then plummeted by 81.43% to $14502.0 in 2023, then skyrocketed by 3380.47% to $504738.0 in 2024, then grew by 8.83% to $549288.0 in 2025.
  • Its Tax Provisions was $549288.0 in Q3 2025, compared to $141205.0 in Q2 2025 and $100509.0 in Q1 2025.